Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer

NICE technology appraisal guidance [TA61]
Published date:
May 2003

NICE has recommended that capecitabine or tegafur with uracil (and folinic acid), to be taken by mouth, should be among the first options considered for a person with metastatic colorectal cancer. The choice about which medicine to take should be made jointly by the patient and his or her doctor, and the patient should be informed about the options and the differences between the medicines so that he or she can be fully involved in the decision.

NICE also noted that the use of capecitabine and tegafur with uracil should be overseen by doctors specialising in the use of medicines for colorectal cancer.

In April 2006, following consultation, the Institute decided to make this guidance 'static.' This means that the guidance remains in force and has no scheduled review date. See the review decision, under 'Background information', for further details.